Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45

Overview of attention for article published in Annals of Neurology, March 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 8 X users
patent: 3 patents

facebook: 8 Facebook pages

Readers on

mendeley: 101 Mendeley
citeulike: 2 CiteULike

So far, Altmetric has seen 9 public wall posts from 8 users.

1000 prayers for Crimson, 15 May 2015

Findlay, A. R., Wein, N., Kaminoh, Y., Taylor, L. E., Dunn, D. M., Mendell, J. R., King, W. M., Pestronk, A., Florence, J. M.…

CureDuchenne, 08 May 2015

When CureDuchenne first funded Prosensa 11 years ago, the original plan was to develop an exon 46 skipping drug for those…

The Flanigan Lab at Nationwide Children's Hospital, 07 May 2015

Learning from patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD): The latest publication from…

Sociedad Española de Fisioterapia en Pediatría (SEFIP), 31 Mar 2015

Ann Neurol. 2015 Apr;77(4):668-74. doi: 10.1002/ana.24365. Epub 2015 Mar 2.

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 5 additional Facebook posts.